RSA Study Using Two Types of Uncemented Acetabular Components and the Uncemented HA Coated Symax Stem

NCT ID: NCT01618084

Last Updated: 2012-06-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-11-30

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Trident Tritanium acetabular component of a total hip prosthesis is a new developed uncemented acetabular component. In this randomized controlled trial (RCT) the tritanium cup will be compared with the Trident HA acetabular component in two equal sized groups. The Symax HA coated stem will be used as femoral component in both groups.

Study Objectives:

* The primary objective is to determine the prosthetic migration of the uncemented acetabular and femoral total hip components using model based RSA technique
* Secondary objectives are on one hand to assess clinical outcome on the other hand assessing patient satisfaction in both groups using Harris Hip Score, Oxford Hip Score, WOMAC, and EQ-5D questionnaires
* Tertiary objective is to assess bone remodeling of the uncemented acetabular components and the HA-coated Symax hip stem using QCT derived from usinf F18-fluoride PET in a cohort of 12 consecutive patients of this RCT

A total of 50 patients will be enrolled in this RCT divided into two equal groups. Patients have to fulfill the inclusion and exclusion criteria.

All evaluations will be done pre-operatively with 2 weeks before surgery, and after surgery at 4 weeks, 3 and 6 months and 1 and 2 years.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tritanium cup

Group Type EXPERIMENTAL

Tritanium acetabular component

Intervention Type DEVICE

Total hip arthroplasty using a tritanium uncemented acetabular component

Trident HA cup

Group Type ACTIVE_COMPARATOR

Tritanium acetabular component

Intervention Type DEVICE

Total hip arthroplasty using a tritanium uncemented acetabular component

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tritanium acetabular component

Total hip arthroplasty using a tritanium uncemented acetabular component

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with a BMI \< 35
* Patients requiring uncemented primary THA
* Primary diagnosis of osteoarthritis

Exclusion Criteria

* patients with acetabular or femoral osteotomy
* Patients who had a THA on the contralateral side within last 6 months
* Female patients who are pregnant or planning pregnancy during the course of the study
* Patients with active or suspected infection
* patients with malignancy
* patients with a systemic disease that would effect the subject's welfare or overall outcome of the study
* Patients with a neuromuscular or neurosensory deficit which would limit the ability to assess the performance of the device
* Patients with systemic or metabolic disorders leading to progressive bone deterioration
* Patients with other illnesses which are likely to affect their outcome
* Patients with known sensitivity to device materials
Minimum Eligible Age

35 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Stryker Orthopaedics

INDUSTRY

Sponsor Role collaborator

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lodewijk Van Rhijn, professor

Role: PRINCIPAL_INVESTIGATOR

Maastricht University Medical centre

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht UMC

Maastricht, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rene ten Broeke, MD

Role: CONTACT

+31 43 387 5038

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Liesbeth Jutten

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NL 33832.068.10

Identifier Type: OTHER

Identifier Source: secondary_id

MEC10-1-068

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

AMIStem-H Radiographic Analysis
NCT02829866 COMPLETED
Exception Cementless Hip Stem
NCT04349046 ACTIVE_NOT_RECRUITING
RSA - ACTIS Hip Stem
NCT04879732 COMPLETED NA